Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 02)
Levetiracetam Tablet, Film Coated
Product Images NDC 43547-222
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43547-222). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Solco Healthcare Us, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 03)
Levetiracetam Structural Formula (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 04)
Figure 1: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 1 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 05)
This appears to be a figure showing the Responder Rate (>50% Reduction From Baseline) for Study 1. It shows the percentages of responders for the Placebo group (N=95) and the Levetiracetam groups taking 1000 mg/day (N=37) and 3000 mg/day (N=101). There is also a note indicating that one of the groups had a statistically significant difference from the placebo group.*
Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 06)
The text provides a figure, labeled as Figure 2, which shows the Responder Rate (>50% Reduction From Baseline) in Study 2, specifically in Period A. There are percentages ranging from 0% to 40% on the y-axis, and two groups identified on the x-axis, Placebo and Levetiracetam, which had different dosages (1000 moj/day and 2000 moj/day) and number of participants in each group (N=111, N=106, N=105). The text also indicates that there were statistically significant results for Levetiracetam versus placebo.*
Figure 3: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 07)
The figure is showing the Responder Rate (>50% Reduction From Baseline) in Study 3 for two drugs, Placebo and Levetiracetam. Levetiracetam is given at a dose of 3000 mg/day (N=180) and Placebo at N=104. The Responder Rate is shown on the Y-axis ranging from 0% to 45%. The X-axis has the percentages ranging from 0% to 50%, in increments of 5% and the two drugs are on the X-axis. The statistical significance of Levetiracetam versus Placebo is also mentioned in the footnote.*
Figure 4: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 08)
The graph in Figure 4 of the study shows the responder rate (2509 reduction from baseline) in two groups of patients receiving placebo or Levetiracetam. Levetiracetam showed a statistically significant difference compared to the placebo group. The vertical axis represents the percentage of patients, while the horizontal axis represents different response rates.*
Figure 5 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 09)
ot-available*
Figure 6: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 10)
The figure 6 shows the responder rate for a 50% reduction from the baseline in PGTC seizures frequency per week for study 7. The placebo (N=84) and Levetiracetam groups were compared, where Levetiracetam group had a statistically significant difference compared to placebo (P < 0.05). The responder rate for Levetiracetam group was 72.2% compared to 45.2% for placebo.*
250 mg 120 Counts (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 11)
500 mg 120 Counts (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 12)
Dipense na gt igh reitantcoianer R only. This is a medication expressed in milligrams of levetiracetam. Store between 20-25°C (68-77°F) unless permitted to be kept between 15-30°C (53-86°F). It is manufactured by Zhejang Hushai Pharmaceutical Co. Ltd in China and distributed by Soiotethowe US LLC in Somerset, NJ 06473, USA. This information provides a brief description of the medication, its format, and guidelines on appropriate storing.*
750 mg 120 Counts (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 13)
This is a medicine labeling text for Levetiracetam Tablets, USP. It contains information such as the recommended storage conditions, dosage instructions, and the manufacturer's details. The tablets are contained in a child-resistant and airtight container and should be stored at a temperature between 15-30°C. The medication should be dispensed along with a medication guide to each patient. The text also provides details of the manufacturer and the composition of the drug. There is a note about an uncoated area on the box.*
1000 mg 60 Counts (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 14)
This is a description of a medication bottle containing Levetiracetam tablets. The container is child-resistant and tamper-resistant. Each tablet contains 1000 mg of the medication. The packaging includes information on dosage. The medication should be stored at a temperature between 15-30°C (53-86°F). The manufacturer is S Zbejong Huahai Pharmaceutical Co. Ltd in China, and it is distributed by Soco Healthcare US, LLC in New Jersey. The product comes with a medication guide.*
Trademark (Image 01)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
